Clinical Trials Browser

Phase 2 × selinexor × Plasma cell × Clear all

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Phase 2 Recruiting

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting

Multiple Myeloma

NCT04717700 2025-03-18

SABLe

Phase 2 Active not recruiting

Multiple Myeloma

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Multiple Myeloma, Neoplasm, Residual

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Phase 2 Unknown

Multiple Myeloma

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma

NCT05170789 2022-05-04

ESdRRMM

Phase 2 Withdrawn

Multiple Myeloma, Recurrence